Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar :

Del Re DP, Amgalan D, Linkermann A, Liu Q and Kitsis RN: Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 99:1765–1817. 2019. View Article : Google Scholar : PubMed/NCBI

Ruparelia N, Chai JT, Fisher EA and Choudhury RP: Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nat Rev Cardiol. 14:133–144. 2017. View Article : Google Scholar :

D'Arcy MS: Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 43:582–592. 2019. View Article : Google Scholar

Bertheloot D, Latz E and Franklin BS: Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cell Mol Immunol. 18:1106–1121. 2021. View Article : Google Scholar :

He S, Wang L, Miao L, Wang T, Du F, Zhao L and Wang X: Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 137:1100–1111. 2009. View Article : Google Scholar : PubMed/NCBI

Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, et al: Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 25:707–725. 2015. View Article : Google Scholar : PubMed/NCBI

Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A and Albert ML: RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells. Science. 350:328–334. 2015. View Article : Google Scholar : PubMed/NCBI

Gupta K, Phan N, Wang Q and Liu B: Necroptosis in cardiovascular disease-a new therapeutic target. J Mol Cell Cardiol. 118:26–35. 2018. View Article : Google Scholar : PubMed/NCBI

Kung G, Konstantinidis K and Kitsis RN: Programmed necrosis, not apoptosis, in the heart. Circ Res. 108:1017–1036. 2011. View Article : Google Scholar : PubMed/NCBI

Zhe-Wei S, Li-Sha G and Yue-Chun L: The role of necroptosis in cardiovascular disease. Front Pharmacol. 9:7212018. View Article : Google Scholar : PubMed/NCBI

Ruan ZH, Xu ZX, Zhou XY, Zhang X and Shang L: Implications of necroptosis for cardiovascular diseases. Curr Med Sci. 39:513–522. 2019. View Article : Google Scholar : PubMed/NCBI

Zhang T, Zhang Y, Cui M, Jin L, Wang Y, Lv F, Liu Y, Zheng W, Shang H, Zhang J, et al: CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 22:175–182. 2016. View Article : Google Scholar : PubMed/NCBI

Wang W, Wang B, Sun S, Cao S, Zhai X, Zhang C, Zhang Q, Yuan Q, Sun Y, Xue M, et al: Inhibition of adenosine kinase attenuates myocardial ischaemia/reperfusion injury. J Cell Mol Med. 25:2931–2943. 2021. View Article : Google Scholar : PubMed/NCBI

Wei B, Zhao H, Hu B, Dai L, Zhang G, Mo L, Huang N, Zou C, Zhang B, Zhou H, et al: T1AM attenuates the hypoxia/reoxygenation-induced necroptosis of H9C2 cardiomyocytes via RIPK1/RIPK3 pathway. Biomed Res Int. 2022:48337912022. View Article : Google Scholar : PubMed/NCBI

Xu T, Ding W, Tariq MA, Wang Y, Wan Q, Li M and Wang J: Molecular mechanism and therapy application of necrosis during myocardial injury. J Cell Mol Med. 22:2547–2557. 2018. View Article : Google Scholar : PubMed/NCBI

Cao J, Zhang J, Qian J, Wang X, Zhang W and Chen X: Ca²⁺/calmodulin-dependent protein kinase II regulation by RIPK3 alleviates necroptosis in transverse arch constriction-induced heart failure. Front Cardiovasc Med. 9:8473622022. View Article : Google Scholar

Zhou T, DeRoo E, Yang H, Stranz A, Wang Q, Ginnan R, Singer HA and Liu B: MLKL and CaMKII are involved in RIPK3-mediated smooth muscle cell necroptosis. Cells. 10:23972021. View Article : Google Scholar : PubMed/NCBI

Maione AS, Cipolletta E, Sorriento D, Borriello F, Soprano M, Rusciano MR, D'Esposito V, Markabaoui AK, De Palma GD, Martino G, et al: Cellular subtype expression and activation of CaMKII regulate the fate of atherosclerotic plaque. Atherosclerosis. 256:53–61. 2017. View Article : Google Scholar

Sun L, Chen Y, Luo H, Xu M, Meng G and Zhang W: Ca²⁺/calmodulin-dependent protein kinase II regulation by inhibitor 1 of protein phosphatase 1 alleviates necroptosis in high glucose-induced cardiomyocytes injury. Biochem Pharmacol. 163:194–205. 2019. View Article : Google Scholar : PubMed/NCBI

Chen Y, Li X, Hua Y, Ding Y, Meng G and Zhang W: RIPK3-mediated necroptosis in diabetic cardiomyopathy requires CaMKII activation. Oxid Med Cell Longev. 2021:66178162021.PubMed/NCBI

Zhang J, Qian J, Cao J, Wang X, Zhang W and Gu X: Ca²⁺/calmodulin-dependent protein kinase II regulation by inhibitor of RIPK3 protects against cardiac hypertrophy. Oxid Med Cell Longev. 2022:79413742022.

Wang X, Zhang J, Qian J, Cao J, Zhang W and Jiang Y: The regulatory mechanism and effect of receptor-interacting protein kinase 3 on phenylephrine-induced cardiomyocyte hypertrophy. J Cardiovasc Pharmacol. 80:236–250. 2022. View Article : Google Scholar : PubMed/NCBI

Fu Y, Jiang T, Sun H, Li T, Gao F, Fan B, Li X, Qin X and Zheng Q: Necroptosis is required for atrial fibrillation and involved in aerobic exercise-conferred cardioprotection. J Cell Mol Med. 25:8363–8375. 2021. View Article : Google Scholar : PubMed/NCBI

Zhou H, Liu L, Ma X, Wang J, Yang J, Zhou X, Yang Y and Liu H: RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. Mol Cell Biochem. 476:1233–1243. 2021. View Article : Google Scholar :

McMullen CJ, Chalmers S, Wood R, Cunningham MR and Currie S: Sunitinib and imatinib display differential cardiotoxicity in adult rat cardiac fibroblasts that involves a role for calcium/calmodulin dependent protein kinase II. Front Cardiovasc Med. 7:6304802021. View Article : Google Scholar : PubMed/NCBI

Reventun P, Sanchez-Esteban S, Cook A, Cuadrado I, Roza C, Moreno-Gomez-Toledano R, Muñoz C, Zaragoza C, Bosch RJ and Saura M: Bisphenol A induces coronary endothelial cell necroptosis by activating RIP3/CamKII dependent pathway. Sci Rep. 10:41902020. View Article : Google Scholar : PubMed/NCBI

Galluzzi L, Kepp O and Kroemer G: RIP kinases initiate programmed necrosis. J Mol Cell Biol. 1:8–10. 2009. View Article : Google Scholar

Ingram JP, Thapa RJ, Fisher A, Tummers B, Zhang T, Yin C, Rodriguez DA, Guo H, Lane R, Williams R, et al: ZBP1/DAI drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1. J Immunol. 203:1348–1355. 2019. View Article : Google Scholar : PubMed/NCBI

Garvin AM, Jackson MA and Korzick DH: Inhibition of programmed necrosis limits infarct size through altered mitochondrial and immune responses in the aged female rat heart. Am J Physiol Heart Circ Physiol. 315:H1434–H1442. 2018. View Article : Google Scholar : PubMed/NCBI

Khoury MK, Gupta K, Franco SR and Liu B: Necroptosis in the pathophysiology of disease. Am J Pathol. 190:272–285. 2020. View Article : Google Scholar :

Cuny GD and Degterev A: RIPK protein kinase family: Atypical lives of typical kinases. Semin Cell Dev Biol. 109:96–105. 2021. View Article : Google Scholar :

Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, Damko E, Moquin D, Walz T, McDermott A, et al: The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 150:339–350. 2012. View Article : Google Scholar : PubMed/NCBI

Moquin DM, McQuade T and Chan FK: CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One. 8:e768412013. View Article : Google Scholar

Zhang J, Yang Y, He W and Sun L: Necrosome core machinery: MLKL. Cell Mol Life Sci. 73:2153–2163. 2016. View Article : Google Scholar : PubMed/NCBI

Meng Y, Davies KA, Fitzgibbon C, Young SN, Garnish SE, Horne CR, Luo C, Garnier JM, Liang LY, Cowan AD, et al: Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis. Nat Commun. 12:67832021. View Article : Google Scholar : PubMed/NCBI

Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X and Wang X: Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 148:213–227. 2012. View Article : Google Scholar : PubMed/NCBI

Feng N and Anderson ME: CaMKII is a nodal signal for multiple programmed cell death pathways in heart. J Mol Cell Cardiol. 103:102–109. 2017. View Article : Google Scholar :

Hudmon A and Schulman H: Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem J. 364:593–611. 2002. View Article : Google Scholar : PubMed/NCBI

Luczak ED and Anderson ME: CaMKII oxidative activation and the pathogenesis of cardiac disease. J Mol Cell Cardiol. 73:112–116. 2014. View Article : Google Scholar : PubMed/NCBI

Beckendorf J, van den Hoogenhof MMG and Backs J: Physiological and unappreciated roles of CaMKII in the heart. Basic Res Cardiol. 113:292018. View Article : Google Scholar : PubMed/NCBI

Gui L, Guo X, Zhang Z, Xu H, Ji YW, Wang RJ, Zhu JH and Chen QH: Activation of CaMKIIδA promotes Ca²⁺ leak from the sarcoplasmic reticulum in cardiomyocytes of chronic heart failure rats. Acta Pharmacol Sin. 39:1604–1612. 2018. View Article : Google Scholar : PubMed/NCBI

Szentesi P, Pignier C, Egger M, Kranias EG and Niggli E: Sarcoplasmic reticulum Ca2+ refilling controls recovery from Ca2+-induced Ca2+ release refractoriness in heart muscle. Circ Res. 95:807–813. 2004. View Article : Google Scholar : PubMed/NCBI

Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, Li N, Santonastasi M, Müller FU, Schmitz W, et al: Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 119:1940–1951. 2009.

Zhu P, Hu S, Jin Q, Li D, Tian F, Toan S, Li Y, Zhou H and Chen Y: Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: A mechanism involving calcium overload/XO/ROS/mPTP pathway. Redox Biol. 16:157–168. 2018. View Article : Google Scholar : PubMed/NCBI

Gonano LA and Petroff MV: Subcellular mechanisms underlying digitalis-induced arrhythmias: Role of calcium/calmodulin-dependent kinase II (CaMKII) in the transition from an inotropic to an arrhythmogenic effect. Heart Lung Circ. 23:1118–1124. 2014. View Article : Google Scholar : PubMed/NCBI

Joiner ML, Koval OM, Li J, He BJ, Allamargot C, Gao Z, Luczak ED, Hall DD, Fink BD, Chen B, et al: CaMKII determines mitochondrial stress responses in heart. Nature. 491:269–273. 2012. View Article : Google Scholar : PubMed/NCBI

Bonora M, Giorgi C and Pinton P: Molecular mechanisms and consequences of mitochondrial permeability transition. Nat Rev Mol Cell Biol. 23:266–285. 2022. View Article : Google Scholar

Zhou Y, Liao J, Mei Z, Liu X and Ge J: Insight into crosstalk between ferroptosis and necroptosis: Novel therapeutics in ischemic stroke. Oxid Med Cell Longev. 2021:99910012021. View Article : Google Scholar : PubMed/NCBI

Kist M and Vucic D: Cell death pathways: Intricate connections and disease implications. EMBO J. 40:e1067002021. View Article : Google Scholar :

Halestrap AP: A pore way to die: The role of mitochondria in reperfusion injury and cardioprotection. Biochem Soc Trans. 38:841–860. 2010. View Article : Google Scholar : PubMed/NCBI

Naryzhnaya NV, Maslov LN and Oeltgen PR: Pharmacology of mitochondrial permeability transition pore inhibitors. Drug Dev Res. 80:1013–1030. 2019. View Article : Google Scholar : PubMed/NCBI

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Katus HA, Lindahl B, Morrow DA, et al: Third universal definition of myocardial infarction. Circulation. 126:2020–2035. 2012. View Article : Google Scholar : PubMed/NCBI

Pollard TJ: The acute myocardial infarction. Prim Care. 27:631–649. vi2000. View Article : Google Scholar : PubMed/NCBI

Lindsey ML, Bolli R, Canty JM Jr, Du XJ, Frangogiannis NG, Frantz S, Gourdie RG, Holmes JW, Jones SP, Kloner RA, et al: Guidelines for experimental models of myocardial ischemia and infarction. Am J Physiol Heart Circ Physiol. 314:H812–H838. 2018. View Article : Google Scholar : PubMed/NCBI

Cabrera-Fuentes HA, Aragones J, Bernhagen J, Boening A, Boisvert WA, Bøtker HE, Bulluck H, Cook S, Di Lisa F, Engel FB, et al: From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: Meeting report from the third international symposium on 'New frontiers in cardiovascular research'. Basic Res Cardiol. 111:692016. View Article : Google Scholar

Hausenloy DJ and Yellon DM: Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest. 123:92–100. 2013. View Article : Google Scholar : PubMed/NCBI

Adameova A, Horvath C, Abdul-Ghani S, Varga ZV, Suleiman MS and Dhalla NS: Interplay of oxidative stress and necrosis-like cell death in cardiac ischemia/reperfusion injury: A focus on necroptosis. Biomedicines. 10:1272022. View Article : Google Scholar : PubMed/NCBI

Mishra PK, Adameova A, Hill JA, Baines CP, Kang PM, Downey JM, Narula J, Takahashi M, Abbate A, Piristine HC, et al: Guidelines for evaluating myocardial cell death. Am J Physiol Heart Circ Physiol. 317:H891–H922. 2019. View Article : Google Scholar : PubMed/NCBI

DeRoo E, Zhou T and Liu B: The role of RIPK1 and RIPK3 in cardiovascular disease. Int J Mol Sci. 21:81742020. View Article : Google Scholar : PubMed/NCBI

Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M, Gautheron J, Roderburg C, Borg N, Reisinger F, et al: RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res. 103:206–216. 2014. View Article : Google Scholar : PubMed/NCBI

Zhang DY, Wang BJ, Ma M, Yu K, Zhang Q and Zhang XW: MicroRNA-325-3p protects the heart after myocardial infarction by inhibiting RIPK3 and programmed necrosis in mice. BMC Mol Biol. 20:172019. View Article : Google Scholar : PubMed/NCBI

Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans PA and Sluijter JP: Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol. 107:2702012. View Article : Google Scholar : PubMed/NCBI

Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T and Tsujimoto Y: Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 434:652–658. 2005. View Article : Google Scholar : PubMed/NCBI

Clarke SJ, McStay GP and Halestrap AP: Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem. 277:34793–34799. 2002. View Article : Google Scholar : PubMed/NCBI

Parks RJ, Menazza S, Holmström KM, Amanakis G, Fergusson M, Ma H, Aponte AM, Bernardi P, Finkel T and Murphy E: Cyclophilin D-mediated regulation of the permeability transition pore is altered in mice lacking the mitochondrial calcium uniporter. Cardiovasc Res. 115:385–394. 2019. View Article : Google Scholar :

Torrance N, Elliott AM, Lee AJ and Smith BH: Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain. 14:380–386. 2010. View Article : Google Scholar

Yang Z, Li C, Wang Y, Yang J, Yin Y, Liu M, Shi Z, Mu N, Yu L and Ma H: Melatonin attenuates chronic pain related myocardial ischemic susceptibility through inhibiting RIP3-MLKL/CaMKII dependent necroptosis. J Mol Cell Cardiol. 125:185–194. 2018. View Article : Google Scholar : PubMed/NCBI

Szobi A, Gonçalvesová E, Varga ZV, Leszek P, Kuśmierczyk M, Hulman M, Kyselovič J, Ferdinandy P and Adameová A: Analysis of necroptotic proteins in failing human hearts. J Transl Med. 15:862017. View Article : Google Scholar :

Lázár E, Sadek HA and Bergmann O: Cardiomyocyte renewal in the human heart: Insights from the fall-out. Eur Heart J. 38:2333–2342. 2017. View Article : Google Scholar : PubMed/NCBI

Chen Y, Li X, Lai W, Zhu F, Tan X, Xian W, Kang P and Wang H: RIP1/RIP3-MLKL signaling pathway correlates with occurrence, progression and prognosis of chronic heart failure. Nan Fang Yi Ke Da Xue Xue Bao. 41:1534–1539. 2021.In Chinese.

Piamsiri C, Maneechote C, Siri-Angkul N, Chattipakorn SC and Chattipakorn N: Targeting necroptosis as therapeutic potential in chronic myocardial infarction. J Biomed Sci. 28:252021. View Article : Google Scholar : PubMed/NCBI

Szobi A, Rajtik T, Carnicka S, Ravingerova T and Adameova A: Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: Effects on programmed necrotic and apoptotic cell death. Mol Cell Biochem. 388:269–276. 2014. View Article : Google Scholar

Zhang T and Brown JH: Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res. 63:476–486. 2004. View Article : Google Scholar : PubMed/NCBI

Kerfant BG, Verheule S and Schotten U: Leaky ryanodine receptors in the failing heart: The root of all evil? Cardiovasc Res. 90:399–401. 2011. View Article : Google Scholar : PubMed/NCBI

Sakalihasan N, Limet R and Defawe OD: Abdominal aortic aneurysm. Lancet. 365:1577–1589. 2005. View Article : Google Scholar : PubMed/NCBI

Baxter BT, Terrin MC and Dalman RL: Medical management of small abdominal aortic aneurysms. Circulation. 117:1883–1889. 2008. View Article : Google Scholar : PubMed/NCBI

Legg JS and Legg LM: Abdominal aortic aneurysms. Radiol Technol. 88:145–163. 2016.

Jiang F, Jones GT and Dusting GJ: Failure of antioxidants to protect against angiotensin II-induced aortic rupture in aged apolipoprotein(E)-deficient mice. Br J Pharmacol. 152:880–890. 2007. View Article : Google Scholar : PubMed/NCBI

López-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA and Thompson RW: Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol. 150:993–1007. 1997.PubMed/NCBI

Guo DC, Papke CL, He R and Milewicz DM: Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci. 1085:339–352. 2006. View Article : Google Scholar : PubMed/NCBI

Wang Q, Liu Z, Ren J, Morgan S, Assa C and Liu B: Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ Res. 116:600–611. 2015. View Article : Google Scholar : PubMed/NCBI

Zhou T, Wang Q, Phan N, Ren J, Yang H, Feldman CC, Feltenberger JB, Ye Z, Wildman SA, Tang W and Liu B: Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 10:2262019. View Article : Google Scholar : PubMed/NCBI

Wang Q, Zhou T, Liu Z, Ren J, Phan N, Gupta K, Stewart DM, Morgan S, Assa C, Kent KC and Liu B: Inhibition of receptor-interacting protein kinase 1 with necrostatin-1s ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model. Sci Rep. 7:421592017. View Article : Google Scholar : PubMed/NCBI

Adamson PD, Dweck MR and Newby DE: The vulnerable atherosclerotic plaque: In vivo identification and potential therapeutic avenues. Heart. 101:1755–1766. 2015. View Article : Google Scholar : PubMed/NCBI

Finney AC, Funk SD, Green JM, Yurdagul A Jr, Rana MA, Pistorius R, Henry M, Yurochko A, Pattillo CB, Traylor JG, et al: EphA2 expression regulates inflammation and fibroproliferative remodeling in atherosclerosis. Circulation. 136:566–582. 2017. View Article : Google Scholar : PubMed/NCBI

Virmani R, Burke AP, Farb A and Kolodgie FD: Pathology of the vulnerable plaque. J Am Coll Cardiol. 47(8 Suppl): C13–C18. 2006. View Article : Google Scholar

Lin J, Li H, Yang M, Ren J, Huang Z, Han F, Huang J, Ma J, Zhang D, Zhang Z, et al: A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 3:200–210. 2013. View Article : Google Scholar : PubMed/NCBI

Karunakaran D, Geoffrion M, Wei L, Gan W, Richards L, Shangari P, DeKemp EM, Beanlands RA, Perisic L, Maegdefessel L, et al: Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2:e16002242016. View Article : Google Scholar : PubMed/NCBI

Liu C, Jiang Z, Pan Z and Yang L: The function, regulation and mechanism of programmed cell death of macrophages in atherosclerosis. Front Cell Dev Biol. 9:8095162021. View Article : Google Scholar

Jang WB, Park JH, Ji ST, Lee NK, Kim DY, Kim YJ, Jung SY, Kang S, Lamichane S, Lamichane BD, et al: Cytoprotective roles of a novel compound, MHY-1684, against hyperglycemia-induced oxidative stress and mitochondrial dysfunction in human cardiac progenitor cells. Oxid Med Cell Longev. 2018:45281842018. View Article : Google Scholar : PubMed/NCBI

Poornima IG, Parikh P and Shannon RP: Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 98:596–605. 2006. View Article : Google Scholar

Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD); Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, et al: ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab Vasc Dis Res. 11:133–173. 2014. View Article : Google Scholar

Wei J, Zhao Y, Liang H, Du W and Wang L: Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharm Sin B. 12:1–17. 2022. View Article : Google Scholar : PubMed/NCBI

Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B and Anversa P: Myocardial cell death in human diabetes. Circ Res. 87:1123–1132. 2000. View Article : Google Scholar : PubMed/NCBI

Chen Y, Hua Y, Li X, Arslan IM, Zhang W and Meng G: Distinct types of cell death and the implication in diabetic cardiomyopathy. Front Pharmacol. 11:422020. View Article : Google Scholar : PubMed/NCBI

Liu YS, Huang ZW, Wang L, Liu XX, Wang YM, Zhang Y and Zhang M: Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats. J Pharmacol Sci. 127:260–274. 2015. View Article : Google Scholar

Liang W, Chen M, Zheng D, He J, Song M, Mo L, Feng J and Lan J: A novel damage mechanism: Contribution of the interaction between necroptosis and ROS to high glucose-induced injury and inflammation in H9c2 cardiac cells. Int J Mol Med. 40:201–208. 2017. View Article : Google Scholar : PubMed/NCBI

Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, Yang J, Glynn P, Sossalla S, Swaminathan PD, et al: Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 123:1262–1274. 2013. View Article : Google Scholar : PubMed/NCBI

Hegyi B, Bers DM and Bossuyt J: CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy. J Mol Cell Cardiol. 127:246–259. 2019. View Article : Google Scholar : PubMed/NCBI

Yamagishi S, Fukami K and Matsui T: Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. Int J Cardiol. 185:263–268. 2015. View Article : Google Scholar : PubMed/NCBI

Simó-Servat O, Planas A, Ciudin A, Simó R and Hernández C: Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinol Diabetes Nutr (Engl Ed). 65:540–545. 2018.PubMed/NCBI

Hua Y, Qian J, Cao J, Wang X, Zhang W and Zhang J: Ca²⁺/calmodulin-dependent protein kinase II regulation by inhibitor of receptor interacting protein kinase 3 alleviates necroptosis in glycation end products-induced cardiomyocytes injury. Int J Mol Sci. 23:69882022. View Article : Google Scholar

Fang L, Beale A, Ellims AH, Moore XL, Ling LH, Taylor AJ, Chin-Dusting J and Dart AM: Associations between fibrocytes and postcontrast myocardial T1 times in hypertrophic cardiomyopathy. J Am Heart Assoc. 2:e0002702013. View Article : Google Scholar : PubMed/NCBI

Maron BJ and Maron MS: Hypertrophic cardiomyopathy. Lancet. 381:242–255. 2013. View Article : Google Scholar

Yao J, Qin X, Zhu J and Sheng H: Dyrk1A-ASF-CaMKIIδ signaling is involved in valsartan inhibition of cardiac hypertrophy in renovascular hypertensive rats. Cardiology. 133:198–204. 2016. View Article : Google Scholar

Li C, Cai X, Sun H, Bai T, Zheng X, Zhou XW, Chen X, Gill DL, Li J and Tang XD: The δA isoform of calmodulin kinase II mediates pathological cardiac hypertrophy by interfering with the HDAC4-MEF2 signaling pathway. Biochem Biophys Res Commun. 409:125–130. 2011. View Article : Google Scholar : PubMed/NCBI

Staerk L, Sherer JA, Ko D, Benjamin EJ and Helm RH: Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circ Res. 120:1501–1517. 2017. View Article : Google Scholar : PubMed/NCBI

Nattel S and Harada M: Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Cardiol. 63:2335–2345. 2014. View Article : Google Scholar

Wakili R, Voigt N, Kääb S, Dobrev D and Nattel S: Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 121:2955–2968. 2011. View Article : Google Scholar : PubMed/NCBI

Calvo D, Filgueiras-Rama D and Jalife J: Mechanisms and drug development in atrial fibrillation. Pharmacol Rev. 70:505–525. 2018. View Article : Google Scholar : PubMed/NCBI

Liu Z, Finet JE, Wolfram JA, Anderson ME, Ai X and Donahue JK: Calcium/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Heart Rhythm. 16:1080–1088. 2019. View Article : Google Scholar : PubMed/NCBI

Lee JM, Yoshida M, Kim MS, Lee JH, Baek AR, Jang AS, Kim DJ, Minagawa S, Chin SS, Park CS, et al: Involvement of alveolar epithelial cell necroptosis in idiopathic pulmonary fibrosis pathogenesis. Am J Respir Cell Mol Biol. 59:215–224. 2018. View Article : Google Scholar : PubMed/NCBI

Wei S, Zhou H, Wang Q, Zhou S, Li C, Liu R, Qiu J, Shi C and Lu L: RIP3 deficiency alleviates liver fibrosis by inhibiting ROCK1-TLR4-NF-κB pathway in macrophages. FASEB J. 33:11180–11193. 2019. View Article : Google Scholar : PubMed/NCBI

Mukherjee S, Sheng W, Sun R and Janssen LJ: Ca²⁺/calmodulin-dependent protein kinase IIβ and IIδ mediate TGFβ-induced transduction of fibronectin and collagen in human pulmonary fibroblasts. Am J Physiol Lung Cell Mol Physiol. 312:L510–L519. 2017. View Article : Google Scholar

Cui H, Zuo S, Liu Z, Liu H, Wang J, You T, Zheng Z, Zhou Y, Qian X, Yao H, et al: The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs. Sci Adv. 6:eabb85432020. View Article : Google Scholar : PubMed/NCBI

Yeh ETH and Bickford CL: Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 53:2231–2247. 2009. View Article : Google Scholar

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D and Cipolla CM: Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 66:309–325. 2016. View Article : Google Scholar

Liang Z, He Y and Hu X: Cardio-oncology: Mechanisms, drug combinations, and reverse cardio-oncology. Int J Mol Sci. 23:106172022. View Article : Google Scholar : PubMed/NCBI

Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS and Moreira PI: Doxorubicin: The good, the bad and the ugly effect. Curr Med Chem. 16:3267–3285. 2009. View Article : Google Scholar

Fer reira AL, Matsubara LS and Matsubara BB: Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem. 6:278–281. 2008. View Article : Google Scholar

Stefenelli T, Kuzmits R, Ulrich W and Glogar D: Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 9:552–556. 1988. View Article : Google Scholar

Lejonc JL, Vernant JP, Macquin J and Castaigne A: Myocardial infarction following vinblastine treatment. Lancet. 2:6921980. View Article : Google Scholar : PubMed/NCBI

Calafat AM, Ye X, Wong LY, Reidy JA and Needham LL: Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect. 116:39–44. 2008. View Article : Google Scholar : PubMed/NCBI

Vandenberg LN, Hauser R, Marcus M, Olea N and Welshons WV: Human exposure to bisphenol A (BPA). Reprod Toxicol. 24:139–177. 2007. View Article : Google Scholar : PubMed/NCBI

Gao X and Wang HS: Impact of bisphenol a on the cardiovascular system-epidemiological and experimental evidence and molecular mechanisms. Int J Environ Res Public Health. 11:8399–8413. 2014. View Article : Google Scholar : PubMed/NCBI

Moon S, Yu SH, Lee CB, Park YJ, Yoo HJ and Kim DS: Effects of bisphenol A on cardiovascular disease: An epidemiological study using national health and nutrition examination survey 2003-2016 and meta-analysis. Sci Total Environ. 763:1429412021. View Article : Google Scholar

Conrad M, Angeli JP, Vandenabeele P and Stockwell BR: Regulated necrosis: Disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 15:348–366. 2016. View Article : Google Scholar : PubMed/NCBI

Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ, Sehon CA, Marquis RW, Bertin J and Mocarski ES: Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 288:31268–31279. 2013. View Article : Google Scholar : PubMed/NCBI

Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, Lich JD, Finger J, Kasparcova V, Votta B, et al: RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 56:481–495. 2014. View Article : Google Scholar : PubMed/NCBI

Lim SY, Davidson SM, Mocanu MM, Yellon DM and Smith CCT: The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther. 21:467–469. 2007. View Article : Google Scholar : PubMed/NCBI

Smith CCT, Davidson SM, Lim SY, Simpkin JC, Hothersall JS and Yellon DM: Necrostatin: A potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 21:227–233. 2007. View Article : Google Scholar : PubMed/NCBI

Zhou H, Hu B and Liu X: Thyroid hormone metabolite 3-iodothyronamine (T1AM) alleviates hypoxia/reoxygenation-induced cardiac myocyte apoptosis via Akt/FoxO1 pathway. Med Sci Monit. 26:e9231952020.PubMed/NCBI

Meng Y, Tao Z, Zhou S, Da W and Tao L: Research hot spots and trends on melatonin from 2000 to 2019. Front Endocrinol (Lausanne). 12:7539232021. View Article : Google Scholar : PubMed/NCBI

Hu Q, Wu D, Ma F, Yang S, Tan B, Xin H, Gu X, Chen X, Chen S, Mao Y and Zhu YZ: Novel angiogenic activity and molecular mechanisms of ZYZ-803, a slow-releasing hydrogen sulfide-nitric oxide hybrid molecule. Antioxid Redox Signal. 25:498–514. 2016. View Article : Google Scholar

Chang L, Wang Z, Ma F, Tran B, Zhong R, Xiong Y, Dai T, Wu J, Xin X, Guo W, et al: ZYZ-803 Mitigates endoplasmic reticulum stress-related necroptosis after acute myocardial infarction through downregulating the RIP3-CaMKII signaling pathway. Oxid Med Cell Longev. 2019:61736852019. View Article : Google Scholar : PubMed/NCBI

Adameova A, Carnicka S, Rajtik T, Szobi A, Nemcekova M, Svec P and Ravingerova T: Upregulation of CaMKIIδ during ischaemia-reperfusion is associated with reperfusion-induced arrhythmias and mechanical dysfunction of the rat heart: Involvement of sarcolemmal Ca2+-cycling proteins. Can J Physiol Pharmacol. 90:1127–1134. 2012. View Article : Google Scholar : PubMed/NCBI

Pallien T and Klussmann E: New aspects in cardiac L-type Ca2+ channel regulation. Biochem Soc Trans. 48:39–49. 2020. View Article : Google Scholar : PubMed/NCBI

Gao H, Wang F, Wang W, Makarewich CA, Zhang H, Kubo H, Berretta RM, Barr LA, Molkentin JD and Houser SR: Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling. J Mol Cell Cardiol. 53:657–667. 2012. View Article : Google Scholar : PubMed/NCBI

Ikeda S, Matsushima S, Okabe K, Ikeda M, Ishikita A, Tadokoro T, Enzan N, Yamamoto T, Sada M, Deguchi H, et al: Blockade of L-type Ca²⁺ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway. Sci Rep. 9:98502019. View Article : Google Scholar

Lim WY, Messow CM and Berry C: Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: A systematic review and meta-analysis. Br J Pharmacol. 165:2034–2043. 2012. View Article : Google Scholar

Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, et al: Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 359:473–481. 2008. View Article : Google Scholar : PubMed/NCBI

Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Elbaz M, Delarche N, et al: Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 373:1021–1031. 2015. View Article : Google Scholar : PubMed/NCBI

Ottani F, Latini R, Staszewsky L, La Vecchia L, Locuratolo N, Sicuro M, Masson S, Barlera S, Milani V, Lombardi M, et al: Cyclosporine A in reperfused myocardial infarction: The multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 67:365–374. 2016. View Article : Google Scholar : PubMed/NCBI

Gill RS, Bigam DL and Cheung PY: The role of cyclosporine in the treatment of myocardial reperfusion injury. Shock. 37:341–347. 2012. View Article : Google Scholar : PubMed/NCBI

Zhang CX, Cheng Y, Liu DZ, Liu M, Cui H, Zhang BL, Mei QB and Zhou SY: Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. J Nanobiotechnology. 17:182019. View Article : Google Scholar : PubMed/NCBI

Yao LL, Huang XW, Wang YG, Cao YX, Zhang CC and Zhu YC: Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol. 298:H1310–H1319. 2010. View Article : Google Scholar : PubMed/NCBI

Kar S, Kambis TN and Mishra PK: Hydrogen sulfide-mediated regulation of cell death signaling ameliorates adverse cardiac remodeling and diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 316:H1237–H1252. 2019. View Article : Google Scholar :

Sun HJ, Wu ZY, Nie XW, Wang XY and Bian JS: An updated insight into molecular mechanism of hydrogen sulfide in cardiomyopathy and myocardial ischemia/reperfusion injury under diabetes. Front Pharmacol. 12:6518842021. View Article : Google Scholar : PubMed/NCBI